Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance

Karyopharm Therapeutics Inc.

2024-Q3 EPS reported -$0.69 revenue$114,695,000

U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.
Net loss $32.1M ($0.26/share) vs $34.5M ($0.30/share) in Q3 2023; R&D expenses increased to $36.1M.
FY2024 total revenue guidance narrowed to $145-155M; XPOVIO revenue guidance narrowed to $110-115M.
Phase 3 SENTRY myelofibrosis trial endpoint changed to Abs-TSS; sample size increased to ~350; top-line data expected 2H 2025.
Cash and investments $133.9M; cash runway into Q1 2026 (excluding $24.5M convertible note due Oct 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.